AIDP prognosis typically involves which of the following?

• A. Most recover with supportive care and immunotherapy
• B. Most do not recover
• C. Always fatal
• D. Recovery occurs only with stem cell therapy

Answer: (B)

AIDP (the Guillain-Barré syndrome demyelinating form) usually has a favorable outlook when patients receive prompt supportive care and immune-based treatment. The core idea is that the autoimmune attack on peripheral nerves causes reversible demyelination, and as the nerves remyelinate and the immune assault subsides, strength typically returns over weeks to months. Treatments like intravenous immunoglobulin or plasmapheresis help shorten the course and reduce the severity, while intensive supportive care prevents complications from weakness or respiratory failure. Because many patients regain near-normal function with time, the prognosis is generally positive with modern management, even though some individuals may have lingering weakness or take longer to recover. The alternatives—saying most do not recover, that it is always fatal, or that recovery requires stem cell therapy—do not fit the typical clinical course or current treatments for AIDP.